The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

It's also a great place to start if you're looking for dividend stocks, as nearly every stock on the Dow Jones Industrial ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck, the Pharma giant with operations in Lansdale, announced on Tuesday that it will build a $1 billion “biologics center ...

Summit Therapeutics' ivonescimab performed well in a phase 3 study. The cancer drug candidate is licensed from a Chinese ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

More than 80% of oncologists participating in a global survey consider insurance a major barrier to timely cancer care.

Here are five cases of companies tied up in device and drug patent litigation since the beginning of 2025: 1. NuVasive infringed five patents from a spine surgeon, a jury determined in April. The jury ...

Summit Therapeutics SMMT reported first-quarter 2025 loss per share of 9 cents, narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago period, the company incurred a loss of ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...